Assenagon Asset Management S.A. Increases Position in Abbott Laboratories $ABT

Assenagon Asset Management S.A. increased its position in shares of Abbott Laboratories (NYSE:ABT) by 333.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,099,203 shares of the healthcare product maker’s stock after purchasing an additional 845,610 shares during the period. Assenagon Asset Management S.A. owned 0.06% of Abbott Laboratories worth $137,719,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ABT. Cloud Capital Management LLC bought a new stake in Abbott Laboratories during the third quarter valued at about $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories in the third quarter worth about $31,000. Delos Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories during the second quarter worth about $32,000. Bridge Generations Wealth Management LLC bought a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $33,000. Finally, Copia Wealth Management purchased a new position in Abbott Laboratories in the 3rd quarter worth approximately $38,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were bought at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last quarter. 0.46% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. BTIG Research cut their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Barclays decreased their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Trading Down 0.6%

ABT stock opened at $104.87 on Tuesday. The firm has a fifty day moving average price of $112.36 and a 200 day moving average price of $122.77. Abbott Laboratories has a fifty-two week low of $104.10 and a fifty-two week high of $139.06. The firm has a market cap of $182.65 billion, a PE ratio of 28.19, a price-to-earnings-growth ratio of 1.68 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the business earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.